Galapagos NV: business update: http://t.co/6w1jppWE
posted 4 days ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
TiGenix (NYSE Euronext: TIG) announced today that it has obtained all the required approvals to start the company's Phase I clinical trial to assess the safety of intra-lymphatic administration of its expanded adipose stem cells product (Cx621). The Phase I will enroll 10 healthy volunteers and the company expects the last volunteer to be dosed in April, with final results reported by June 2012. Cx621 aims to capitalize on the benefits of TiGenix's proprietary approach of intra-lymphatic administration to treat autoimmune disorders.
"We are delighted that we can start the Phase I trial with Cx621," said Eduardo Bravo, CEO of TiGenix. "We expect that the intra-lymphatic route of administration is not only feasible, but has the potential to become an important alternative next to other administration routes, and may prove to be a very promising new approach in combating autoimmune disorders with expanded allogeneic stem cells."
Cx621 is an allogeneic eASC product candidate for the treatment of autoimmune diseases via a proprietary technique of intra-lymphatic or intra-nodal administration. The intra-lymphatic route is expected to offer significant benefits, as the systemic effect of the cells has been shown to be mediated at the level of the secondary lymphoid organs, the draining lymph nodes and spleen. Recent preclinical and clinical experience with vaccines and antitumor agents indicate that the lymph nodes may provide a feasible and safe route of administration. Indeed, the subcutaneous lymph nodes are readily visible by ultrasound and injection of a superficial lymph node in the groin area can be performed quickly and without prior training. Patients rated intra-lymphatic injection less painful than venous puncture (Senti et al., 2008).
TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with two marketed products, ChondroCelect and ChondroMimetic, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium), and has facilities in Madrid (Spain), Cambridge (UK) and Sittard-Geleen (the Netherlands). For more information please visit www.tigenix.com.
Source: TiGenix
Tags: clinical trials
Bookmark this:
